Vivek Subbiah: Best oncology colleagues in the universe

Petros Grivas shared a post by Vivek Subbiah on X, adding:

“Fantastic ESMO24.

Wonderful group with diversity, talent, passion and love for oncology! Looking forward to next days!”

Quoting Vivek Subbiah‘s post:

“Meeting with the best of the best oncology colleagues in the universe.

Thank you to ESMO for bringing us all together. It takes a global village.”

Source: Petros Grivas/X and Vivek Subbiah/X 

Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.